Demyelinating Syndromes (Optic Neuritis, Transverse Myelitis, ADEM)

Neurological Conditions

(908) 379-3979 https://www.premierneurohealth.com/

Demyelinating Syndromes (Optic Neuritis, Transverse Myelitis, ADEM) & Neuromyelitis Optica Spectrum Disorders (NMOSD)

Demyelinating syndromes represent a group of inflammatory autoimmune attacks against the central nervous system (CNS), leading to acute or subacute neurological symptoms involving vision, movement, sensation, coordination, and bladder/bowel function. These episodes may occur as isolated events or as part of a broader neuroimmunological disease such as multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD).
The most common isolated demyelinating syndromes include:

Optic Neuritis (ON) – inflammation of the optic nerve causing vision loss and pain with eye movement.
Transverse Myelitis (TM) – inflammation across one segment of the spinal cord causing weakness, numbness, or bladder dysfunction.
Acute Disseminated Encephalomyelitis (ADEM) – widespread inflammation of brain and spinal cord, usually following infection and more common in children.

These conditions must also be distinguished from Neuromyelitis Optica Spectrum Disorders (NMOSD)—a severe antibody-mediated disease primarily affecting the optic nerves and spinal cord, associated with AQP4-IgG or MOG-IgG antibodies.
Prompt recognition and treatment are essential because early immunotherapy can dramatically improve long-term outcomes and prevent irreversible neurological damage.

Questions to Ask Your Doctor

• Is this episode isolated, or does it suggest MS, NMOSD, or MOG-associated disease?
• What imaging findings or antibodies support the diagnosis?
• Do I need a spinal tap, MRI of brain/spine, or visual evoked potentials?
• Should we test for AQP4-IgG and MOG-IgG antibodies?
• What is the risk of relapse, and how do we prevent new attacks?
• Do I need high-dose steroids, plasma exchange, or long-term immunotherapy?
• How do we monitor recovery of vision, strength, or sensation?
• What symptoms require urgent reevaluation?
• Can rehabilitation improve mobility, balance, or daily functioning?

Overview

Demyelinating syndromes arise when the immune system attacks the myelin coating of CNS nerves. Depending on the location of inflammation, individuals may experience vision loss, limb weakness, sensory deficits, gait disturbance, bowel/bladder problems, or encephalopathy.

These episodes fall into two broad categories:

Monophasic demyelination — single event, may fully recover (e.g., typical optic neuritis, some cases of TM, ADEM).
Relapsing or evolving disease — part of a chronic autoimmune condition such as MS, NMOSD, or MOGAD.

Understanding the underlying pathology is essential because prognosis and treatment strategies differ substantially.

DEMYELINATING SYNDROMES

1. Optic Neuritis (ON)

Clinical Features

• Subacute, often unilateral vision loss
• Pain with eye movement
• Loss of color vision (dyschromatopsia)
• Central scotoma or blurred vision
• Afferent pupillary defect

What Makes ON More Likely?

• Young adult onset
• Vision worsens over 1–7 days
• Pain with eye movement
• MRI showing optic nerve enhancement

Causes

• MS-associated ON (most common)
• MOG antibody–associated disease (MOGAD)
• NMOSD (AQP4-IgG–positive)
• Post-infectious or idiopathic

2. Transverse Myelitis (TM)

Clinical Features

• Bilateral leg or arm weakness
• Numbness, tingling, or sensory level on torso
• Bowel or bladder dysfunction
• Back pain
• Gait disturbance

Patterns

• Partial TM — often MS
• Longitudinally extensive TM (LETM, >3 vertebral segments) — highly suggestive of NMOSD or MOGAD

3. Acute Disseminated Encephalomyelitis (ADEM)

Clinical Features

• Encephalopathy (confusion, lethargy)
• Multifocal neurological deficits
• Ataxia, weakness, seizures
• Often follows viral illness or vaccination
• More common in children

MRI Pattern

• Large, diffuse, poorly defined lesions in brain and sometimes spinal cord
• Often bilateral and symmetric

NEUROMYELITIS OPTICA SPECTRUM DISORDERS (NMOSD)

NMOSD is a severe autoimmune disorder in which antibodies target aquaporin-4 (AQP4) channels on astrocytes, leading to intense inflammation of optic nerves and spinal cord. Without rapid treatment, NMOSD attacks can cause profound, irreversible disability.

Key Features Suggesting NMOSD

• Recurrent optic neuritis
• Bilateral or severe ON
• Transverse myelitis involving ≥3 vertebral segments
• Intractable hiccups, nausea (area postrema syndrome)
• Persistent, severe pain
• Poor recovery from initial attack

Types

AQP4-IgG–positive NMOSD — classic form.
Seronegative NMOSD — diagnosis based on clinical features + MRI (rare).
MOG-IgG Disease (MOGAD) — distinct entity that can mimic NMOSD or MS but has better recovery and different treatment.

Signs and Symptoms

Optic Neuritis

• Blurred or dim vision
• Pain with eye movement
• Color desaturation
• Visual field loss

Transverse Myelitis

• Limb weakness
• Sensory changes
• Heightened reflexes or spasticity
• Bladder urgency or retention

ADEM

• Altered mental status
• Seizures
• Multifocal deficits
• Headache or fever

NMOSD

• Severe, recurrent ON
• LETM with marked weakness
• Persistent vomiting/hiccups (area postrema)
• Severe neuropathic pain
• Poor spontaneous recovery

Exams and Tests

1. MRI Brain and Spine

• Optic nerve enhancement (ON)
• Cervical or thoracic lesions (TM)
• LETM (>3 segments) → NMOSD/MOGAD
• Large ADEM lesions

2. Lumbar Puncture

• Oligoclonal bands → suggests MS
• Markedly elevated protein in TM
• Absence of OCBs with LETM → raises concern for NMOSD

3. Serum Antibody Testing (Mandatory)

• AQP4-IgG — NMOSD
• MOG-IgG — MOG-associated demyelination

4. Evoked Potentials

• Visual evoked potentials for ON
• Somatosensory evoked potentials for myelitis

5. Routine Labs

To exclude mimics:
• B12, copper
• ANA, ENA
• Thyroid function
• Lyme, syphilis, HIV
• ESR/CRP

6. Advanced Biomarkers

• Neurofilament light chain (NfL) — axonal injury
• GFAP — astrocytic injury (elevated in NMOSD)

Treatment

Treatment depends on whether the event is isolated or part of chronic disease.

Acute Attack Management (All Forms)

• High-dose IV methylprednisolone (first-line)
• Plasma exchange (PLEX) for severe attacks or steroid non-responders
• IVIG (select cases, especially MOGAD or pediatric demyelination)

Early treatment can significantly improve vision, mobility, and long-term function.

Long-Term Disease Prevention

For MS-like monophasic ON or TM

Treatment varies depending on recurrence risk and MRI features.

For NMOSD (AQP4-IgG positive) — Always requires long-term therapy

• Eculizumab (C5 inhibitor)
• Inebilizumab (anti-CD19)
• Satralizumab (IL-6 receptor blocker)

These therapies dramatically reduce relapse risk and disability progression.

For MOGAD

• Long-term therapy only if relapsing (steroids, IVIG, mycophenolate, rituximab)
• Generally better recovery than NMOSD

Symptom Management

• Neuropathic pain medications
• Bowel/bladder management
• Spasticity treatment (baclofen, tizanidine)
• Mobility aids and PT/OT
• Vision rehabilitation for ON

Living With Demyelinating Syndromes & NMOSD

Individuals often improve significantly with early treatment, structured follow-up, and multidisciplinary support.

Effective strategies:

• Regular MRI monitoring
• Early recognition of relapse symptoms
• Avoiding overheating and infections
• Vitamin D optimization
• Anti-inflammatory nutrition
• Stress reduction and sleep optimization

NMOSD requires lifelong immunotherapy to prevent relapses, while many cases of ON, TM, or ADEM are monophasic.

Did You Know?

• Transverse myelitis that spans >3 vertebral segments is highly suggestive of NMOSD.
• MOGAD often affects children and young adults and has excellent recovery with steroids.
• AQP4 antibodies target astrocytes—not myelin—leading to secondary demyelination.
• ADEM is typically a one-time event and often follows infection.
• Optic neuritis associated with MS usually recovers well within weeks to months.

References

Wingerchuk DM, Banwell B, Bennett JL, et al. International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders. Neurology. 2015;85(2):177-189.[1]

https://pubmed.ncbi.nlm.nih.gov/26092914

International consensus criteria for NMOSD: six core clinical characteristics (optic neuritis, acute myelitis, area postrema syndrome, brainstem syndrome, narcolepsy, cerebral syndrome); AQP4-IgG testing required; diagnostic algorithm

Papadopoulos MC, Verkman AS. Aquaporin 4 and Neuromyelitis Optica. Lancet Neurol. 2012;11(6):535-544.

https://pubmed.ncbi.nlm.nih.gov/22608667

AQP4 water channels on astrocyte foot processes; AQP4-IgG binding triggers complement activation, granulocyte infiltration, astrocyte destruction, secondary demyelination; longitudinally extensive spinal cord lesions characteristic

Weinshenker BG, Wingerchuk DM. Neuromyelitis Optica: Clinical Syndrome and the NMO-IgG Autoantibody Marker. Curr Top Microbiol Immunol. 2008;318:343-356.

https://pubmed.ncbi.nlm.nih.gov/18219825

Clinical features distinguishing NMOSD from MS: severe attacks with poor recovery, bilateral/recurrent optic neuritis, longitudinally extensive transverse myelitis ≥3 vertebral segments, area postrema syndrome

Levy M, Fujihara K, Palace J. New Therapies for Neuromyelitis Optica Spectrum Disorder. Lancet Neurol. 2021;20(1):60-67.[2]

https://pubmed.ncbi.nlm.nih.gov/33340490

Review of NMOSD therapies: eculizumab (complement C5 inhibitor), inebilizumab (anti-CD19 B-cell depletion), satralizumab (IL-6 receptor blockade); all reduce annualized relapse rate by 73-79%

Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of Aquaporin-4 Autoimmunity and Neuromyelitis Optica Spectrum. Ann Neurol. 2016;79(5):775-783.

https://pubmed.ncbi.nlm.nih.gov/26990317

NMOSD epidemiology: prevalence 0.5-10 per 100,000; female:male ratio 9:1; higher prevalence in non-white populations; median age onset 39 years; 10% seronegative

NMOSD Treatment Trials (3 references):

Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 3 Trial. Lancet. 2019;394(10206):1352-1363.[1]

https://pubmed.ncbi.nlm.nih.gov/31495497

N-MOmentum trial: eculizumab reduced adjudicated relapse risk by 94% vs placebo in AQP4-IgG+ NMOSD; complement C5 inhibitor blocks terminal complement activation

Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial. Lancet. 2019;394(10206):1352-1363.[2]

https://pubmed.ncbi.nlm.nih.gov/31495497

N-MOmentum trial: inebilizumab (anti-CD19) reduced attack risk by 73% in AQP4-IgG+ patients, 78% in all NMOSD; B-cell depletion mechanism

Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(22):2114-2124.

https://www.nejm.org/doi/full/10.1056/NEJMoa1901747

SAkuraSky trial: satralizumab (IL-6 receptor blocker) reduced relapse risk by 62% overall, 79% in AQP4-IgG+ patients; subcutaneous administration; can be used as monotherapy

MOG Antibody-Associated Disease (4 references):

Jarius S, Paul F, Aktas O, et al. MOG Encephalomyelitis: International Recommendations on Diagnosis and Antibody Testing. J Neuroinflammation. 2018;15(1):134.

https://pubmed.ncbi.nlm.nih.gov/29724224

MOG-IgG diagnostic recommendations: cell-based assays required (not ELISA); testing indicated for optic neuritis, transverse myelitis, ADEM, NMOSD-like presentations; repeat testing if initially negative

Banwell B, Bennett JL, Marignier R, et al. Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: International MOGAD Panel Proposed Criteria. Lancet Neurol. 2023;22(3):268-282.

https://pubmed.ncbi.nlm.nih.gov/36657752

- 2023 international diagnostic criteria for MOGAD: clinical attack + MOG-IgG (cell-based assay) + reasonable exclusion of alternatives; distinct from MS and NMOSD; 25-50% monophasic

11. Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical Spectrum and Prognostic Value of CNS MOG Autoimmunity in Adults: The MOGADOR Study. Neurology. 2018;90(21):e1858-e1869.

https://pubmed.ncbi.nlm.nih.gov/29695598

- MOGADOR study: adult MOG-IgG disease phenotypes include optic neuritis (58%), myelitis (18%), ADEM (6%), brainstem/cerebral cortical encephalitis; 50% relapsing; better recovery than AQP4-NMOSD

12. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction Between MOG Antibody-Positive and AQP4 Antibody-Positive NMO Spectrum Disorders. Neurology. 2014;82(6):474-481.

https://pubmed.ncbi.nlm.nih.gov/24415568

- Distinguishing features: MOG-IgG associated with simultaneous bilateral optic neuritis, conus involvement in myelitis, better recovery, less female predominance vs AQP4-NMOSD

Optic Neuritis (3 references):

Bennett JL, de Seze J, Lana-Peixoto M, et al. Neuromyelitis Optica and Multiple Sclerosis: Seeing Differences Through Optical Coherence Tomography. Mult Scler. 2015;21(6):678-688.

https://pubmed.ncbi.nlm.nih.gov/25662345

- OCT in optic neuritis: MS-associated ON shows mild-moderate RNFL thinning; NMOSD shows severe microcystic macular edema and profound RNFL loss; MOG intermediate

14. Toosy AT, Mason DF, Miller DH. Optic Neuritis. Lancet Neurol. 2014;13(1):83-99.

https://pubmed.ncbi.nlm.nih.gov/24331794

- Comprehensive ON review: subacute monocular vision loss with pain; high-dose IV methylprednisolone accelerates recovery but doesn't affect final visual outcome; 50% MS risk at 15 years if MRI lesions present

15. Beck RW, Cleary PA, Anderson MM, et al. A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis. N Engl J Med. 1992;326(9):581-588.

https://www.nejm.org/doi/full/10.1056/NEJM199202273260901

- Landmark Optic Neuritis Treatment Trial: IV methylprednisolone (1g/day × 3 days) accelerated visual recovery; oral prednisone alone increased recurrence risk; established standard of care

Transverse Myelitis & ADEM (3 references):

West TW, Hess C, Cree BAC. Acute Transverse Myelitis: Demyelinating, Inflammatory, and Infectious Myelopathies. Semin Neurol. 2012;32(2):97-113.

https://pubmed.ncbi.nlm.nih.gov/22961311

- Diagnostic approach to transverse myelitis: distinguish partial vs complete; short vs longitudinally extensive (LETM ≥3 segments suggests NMOSD/MOGAD); parenchymal vs meningeal enhancement patterns

17. Flanagan EP, Weinshenker BG, Krecke KN, et al. Short Myelitis Lesions in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders. JAMA Neurol. 2015;72(1):81-87.

https://pubmed.ncbi.nlm.nih.gov/25384099

- 14% of AQP4-IgG+ NMOSD patients present with short cord lesions (<3 segments); can evolve to LETM; clinical severity and CSF pleocytosis help distinguish from MS

18. Pohl D, Alper G, Van Haren K, et al. Acute Disseminated Encephalomyelitis: Updates on an Inflammatory CNS Syndrome. Neurology. 2016;87(9 Suppl 2):S38-45.

https://pubmed.ncbi.nlm.nih.gov/27572860

- ADEM diagnostic criteria: encephalopathy (required) + multifocal CNS symptoms; MRI shows large, poorly demarcated lesions; typically monophasic; often post-infectious; distinguish from first MS attack

Treatment & Recovery (2 references):

Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis Optica: Evaluation of 871 Attacks and 1,153 Treatment Courses. Ann Neurol. 2016;79(2):206-216.

https://pubmed.ncbi.nlm.nih.gov/26537743

- Large NMOSD treatment study: high-dose corticosteroids first-line (77% attacks); plasma exchange for steroid failures reduced disability; early treatment (within 7 days) associated with better outcomes

20. Bonnan M, Valentino R, Debeugny S, et al. Short Delay to Initiate Plasma Exchange Is the Strongest Predictor of Outcome in Severe Attacks of NMO Spectrum Disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346-351.

https://pubmed.ncbi.nlm.nih.gov/29101261

• Wingerchuk DM et al. International consensus diagnostic criteria for NMOSD. Neurology. 2015; updated reviews 2020–2023.
• Flanagan EP. Idiopathic transverse myelitis: emerging biomarkers and phenotypes. Lancet Neurol. 2021.
• Sato DK et al. MOG-IgG–associated disease: clinical features and treatment. J Neurol Neurosurg Psychiatry. 2022.
• Jarius S, Wildemann B. AQP4-antibody positive NMOSD: current therapies and outcomes. Front Neurol. 2021.
• Waldman A et al. ADEM and pediatric demyelinating syndromes. Nat Rev Neurol. 2020.
Source: https://www.premierneurohealth.com/